These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 33936103

  • 21. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
    Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T, Wada S.
    Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
    [Abstract] [Full Text] [Related]

  • 22. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Jung EH, Jang HR, Kim SH, Suh KJ, Kim YJ, Lee JH, Chung JH, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.
    Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
    [Abstract] [Full Text] [Related]

  • 23. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y, Luo H, Zheng XL, Ge H.
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, Fiorentino M, Ardizzoni A.
    Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J, Batra A, Boldt G, Shah PS, Blanchette P, Rodrigues G, Vincent MD.
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [Abstract] [Full Text] [Related]

  • 29. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
    Raza A, Mohsen R, Kanbour A, Zar Gul AR, Philip A, Vijayakumar S, Hydrose S, Prabhu KS, Al-Suwaidi AK, Inchakalody VP, Merhi M, Abo El-Ella DM, Tauro MA, Akbar S, Al-Bozom I, Abualainin W, Al-Abdulla R, Sirriya SA, Hassnad S, Uddin S, Mohamed Ibrahim MI, Al Homsi U, Demime S.
    Front Immunol; 2023 Mar; 14():1157100. PubMed ID: 37256148
    [Abstract] [Full Text] [Related]

  • 30. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X, Xu H, Xue Q, Wen R, Jiao W, Tian K.
    Mol Med; 2021 Oct 07; 27(1):126. PubMed ID: 34620079
    [Abstract] [Full Text] [Related]

  • 31. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X.
    Cancer Med; 2021 Feb 07; 10(4):1222-1239. PubMed ID: 33465302
    [Abstract] [Full Text] [Related]

  • 32. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
    Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, Wang S, Shen Y, Zhong R, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X.
    J Immunother Cancer; 2024 Apr 18; 12(4):. PubMed ID: 38641349
    [Abstract] [Full Text] [Related]

  • 33. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ, Ren A, Zheng L, Zheng ED, Jiang T.
    Front Immunol; 2021 Apr 18; 12():651086. PubMed ID: 34248939
    [Abstract] [Full Text] [Related]

  • 34. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P, Ofiara L, Beaudoin S, Wang H, Benedetti A, Gonzalez AV.
    Chest; 2021 Aug 18; 160(2):743-753. PubMed ID: 33675792
    [Abstract] [Full Text] [Related]

  • 35. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Ren P, Liu D, Li W.
    Cancer Med; 2019 Jul 18; 8(8):4023-4031. PubMed ID: 31165589
    [Abstract] [Full Text] [Related]

  • 36. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D, Tian L, Zhu Y, Wo Y, Liu Q, Liu S, Li H, Hou H.
    Mol Med; 2020 Aug 13; 26(1):78. PubMed ID: 32791957
    [Abstract] [Full Text] [Related]

  • 37. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB.
    Cancer; 2021 Mar 01; 127(5):709-719. PubMed ID: 33119177
    [Abstract] [Full Text] [Related]

  • 38. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
    Lung Cancer; 2019 Feb 01; 128():113-119. PubMed ID: 30642442
    [Abstract] [Full Text] [Related]

  • 39. Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
    Shao MM, Xu YP, Zhang JJ, Mao M, Wang MC.
    Clin Transl Oncol; 2024 Jun 01; 26(6):1446-1458. PubMed ID: 38190035
    [Abstract] [Full Text] [Related]

  • 40. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q, Shang X, Liu N, Ma X, Han W, Wang X, Liu Y.
    Front Immunol; 2022 Jun 01; 13():931718. PubMed ID: 35990690
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.